In a recent study published in Nature Communications entitled "Maladaptive positive feedback production of ChREBPβ underlies glucotoxic β-cell failure", scientists from the Icahn School of Medicine at Mount Sinai and other institutions identified a specific therapeutic target that protects and regenerates pancreatic β-cells which help the body produce and distribute insulin. This research may help prevent insulin tolerance in the body and thus provide significant health benefits to millions of people worldwide.
A lack of pancreatic β cells is the root cause of all major types of diabetes. When the body's blood glucose level rises, for example in response to a high-fat diet, the pancreatic β-cells respond by producing and releasing more insulin, which keeps the body's blood glucose level under control. However, persistent hyperglycemia can impair pancreatic β-cells' capacity to produce and secrete insulin, creating a vicious cycle in which the body's glucose level rises while pancreatic β-cell function declines and eventually dies, a condition known as "glucose toxicity." Therefore, the protection and regeneration of pancreatic β-cells is a therapeutic goal in diabetes.
In this study, the researchers identified a molecular mechanism that appears to be involved in the protection and regeneration of β cells, which primarily involves carbohydrate-responsive element binding protein (ChREBP), the production of the highly reactive isoform of this which, is necessary to produce more pancreatic β-cells to cope with the increased insulin demand of the body caused by a high-fat diet or significant glucose exposure. However, a prolonged increase in glucose metabolism may lead to a vicious cycle in which ChREBPβ is overproduced, leading to glucose toxicity and subsequent death of pancreatic β-cells.
The researchers found that by increasing the expression of another form of the protein, ChREBPα, or by activating nuclear factor-erythroid factor 2 (Nrf2, a specific protein that protects cells from oxidative damage) in mouse and human pancreatic β cells might be able to counteract the effects of ChREBPβ and the β cell death observed by the researchers, thus preserving β cell cell cell volume.
Researcher Donald Scott mentioned, "traditionally, ChREBP has been considered a mediator of specific glucose toxicity, but we noticed that a form, ChREBPa, appears to protect β-cells. Analysis of these isoforms revealed that ChREBPβ plays a key role in the progressive destruction of β-cells". This suggests that it may be a marker of hypertension and glucose toxicity in the human organism.
The researchers discovered that blocking ChREBPβ or pharmacologically inhibiting its activity may mitigate the effects of glucose toxicity and safeguard these cells. This exciting discovery may create an opportunity to help develop agents that target this molecular mechanism to effectively block the production of ChREBPβ and protect β-cell cytokinesis.
The findings of this study demonstrate that adaptive and non-adaptive ChREBP β protein are significant regulators of β cell fate and a potential target for preserving pancreatic β cells in the diabetic organism. The findings of this study could not only assist in resolving a long-standing problem for diabetes researchers, but also help prevent insulin dependence in type 2 diabetes patients brought on by a deficiency in β cell volume, which can have a significant impact on patient outcomes and quality of life.
According to the report published by Allied Market Research, the global biotech ingredients market was pegged at $51.3 billion in 2020 and is estimated to hit $75.3 billion by 2028, registering a CAGR of 4.8% from 2021 to 2028.
The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends.Shift in consumer preference from synthetic to bio-based ingredients and development in biotechnology fuel the growth of the global biotech ingredients market.
On the other hand, limited availability of raw materials restrains the growth to some extent.
However, favorable government policies and technological advancements in bio-engineering are expected to create lucrative opportunities in the industry.Request PDF Brochure: https://www.alliedmarketresearch.com/request-sample/11710COVID-19 scenario-The outbreak of the pandemic has given way to either closure or suspension of production activities in most industrial units across the globe, which has impacted the market negatively.Nevertheless, initiation of mass vaccination in most countries is projected to mend the global situation and market is expected to get back on track soon.The global biotech ingredients market is analyzed across type, product, expression systems, and region.
The biosimilars segment, on the other hand, would exhibit the fastest CAGR of 5.0% during the forecast period.Based on product, the monoclonal antibodies segment contributed to more than one-fifth of the total market revenue in 2020 and is expected to dominate by 2028.
However, the hormones and growth factors segment would cite the fastest CAGR of 5.5% during from 2021 to 2028.Get Detailed COVID-19 Impact Analysis on the Biotech Ingredients Market: https://www.alliedmarketresearch.com/request-for-customization/11710?reqfor=covidBased on region, Europe held the major share in 2020, garnering nearly two-fifths of the global market.
